RxDoctor Payments DataLook up a doctor →

Victor Grigoriev, MD

Urology · Las Vegas, NVNPI 1720173602

Payments from drug & device makers

$58,558in general payments, 2019–2025

Across 521 payments — averaging $112.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Caldera Medical, Inc$40K
  • Intuitive Surgical$7K
  • Medtronic$2K
  • Astellas Pharma US Inc$1K
  • Dendreon Pharmaceuticals LLC$1K
  • Sumitomo Pharma America, Inc.$925
  • plus $7K from 51 others

What the payments were for

  • Consulting fees$38,20065%
  • Speaking & faculty fees$1,0752%
  • Travel & lodging$1,5903%
  • Food & beverage$13,39923%
  • Education$4,0887%
  • Gifts$2070%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,558 in reported general payments places this provider in the 90th percentile of 63 urology providers in Nevada.

See all urology providers in Nevada

Medicare billing

Part B allowed, 2024
$634,252
Medicare patients
1,038
Services billed
17,452

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide24$336,791
GemtesaVibegron155$100,504
MyrbetriqMirabegron137$93,401
Estradiol55$3,244
Tamsulosin Hcl265$3,097
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst156$2,585
Methenamine Hippurate34$1,891
Solifenacin Succinate50$1,428
Tadalafil17$1,062
Finasteride86$885
NitrofurantoinNitrofurantoin Macrocrystal36$877
Ciprofloxacin Hcl189$861
Oxybutynin Chloride ErOxybutynin Chloride63$772
Trospium Chloride13$709
Cephalexin54$640

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,412$430,192161 claims
Sumitomo Pharma America, Inc.Gemtesa$925$100,504155 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 63 urology providers in Nevada.

Other urology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →